Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6631 to 6645 of 7707 results

  1. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued [GID-TAG417]

    Technology appraisal guidance
    Discontinued

  2. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued [GID-TA10429]

    Technology appraisal guidance
    Discontinued

  3. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued [GID-TAG511]

    Technology appraisal guidance
    Discontinued

  4. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued [GID-TAG280]

    Technology appraisal guidance
    Discontinued

  5. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued [GID-TAG454]

    Technology appraisal guidance
    Discontinued

  6. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued [GID-TA10065]

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued [GID-TA10418]

    Technology appraisal guidance
    Discontinued

  8. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued [GID-TA10452]

    Technology appraisal guidance
    Discontinued

  9. Colon cancer (adjuvant) - irinotecan [ID379]

    In development [GID-TAG380] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued [GID-TA10168]

    Technology appraisal guidance
    Discontinued

  11. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued [GID-TAG435]

    Technology appraisal guidance
    Discontinued

  12. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued [GID-TA10018]

    Technology appraisal guidance
    Discontinued

  13. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued [GID-TA10105]

    Technology appraisal guidance
    Discontinued

  14. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued [GID-TAG440]

    Technology appraisal guidance
    Discontinued

  15. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

    Technology appraisal guidance
    Discontinued